In patients with advanced non-squamous NSCLC, activating mutations in the epidermal growth factor receptor (EGFR)—particularly exon 19 deletions and exon 21 L858R substitutions—constitute key therapeutic targets [5,6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.